Nanite

Founded in 2019 and based in Cambridge, USA, Nanite is a private, pre-clinical biotech leveraging a proprietary AI platform called SAYER to engineer polymer nanoparticles for genetic drug delivery. The platform integrates computational design, automated synthesis, and multi-modal biological screening to rapidly identify PNPs with optimal tissue targeting, expression, and safety profiles. Nanite is initially targeting genetic diseases, with disclosed work in cystic fibrosis and an HIV gene therapy project funded by the Gates Foundation, positioning itself as a potential disruptor in the gene therapy delivery space.

SAYER™: An AI-powered, closed-loop platform that integrates computational polymer design, high-throughput synthesis & characterization, multiplexed in vivo screening, and machine learning to engineer tissue-specific polymer nanoparticles (PNPs) for gene delivery.

Nanite competes in the crowded gene delivery space against established viral vector companies, LNP developers (e.g., those used in mRNA vaccines), and other biotechs exploring novel lipid, polymer, and virus-like particle technologies. Its key differentiator is the integrated use of AI and high-throughput in vivo multiplexing to systematically decode and design polymer-biology interactions.